Live Breaking News & Updates on தொடர்ந்து லைம்

Stay updated with breaking news from தொடர்ந்து லைம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Flightpath Bio Launches via Illumina Accelerator for Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).
Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic
Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes ....

United States , Matt Tindall , Michael Bellas , Flightpath Biosciences Inc , Flightpath Biosciences , Illumina Accelerator , Persistent Lyme Disease , Flightpath Co Founder , Persistent Lyme , Mark De Souza , ஒன்றுபட்டது மாநிலங்களில் , மேட் டிண்டால் , மைக்கேல் பெல்லாஸ் , இல்லுமின முடுக்குப்பொறி , தொடர்ந்து லைம் நோய் , தொடர்ந்து லைம் , குறி டி ஸூஸ ,

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).
Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic
Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes ....

United States , Matt Tindall , Michael Bellas , Flightpath Biosciences Inc , Flightpath Biosciences , Illumina Accelerator , Persistent Lyme Disease , Flightpath Co Founder , Persistent Lyme , Mark De Souza , California Business , Health And Medical , Lyme Disease , Medical Research , Product Launches , ஒன்றுபட்டது மாநிலங்களில் , மேட் டிண்டால் , மைக்கேல் பெல்லாஸ் , இல்லுமின முடுக்குப்பொறி , தொடர்ந்து லைம் நோய் , தொடர்ந்து லைம் , குறி டி ஸூஸ , உயிரி தொழில்நுட்பவியல் , கலிஃபோர்னியா வணிக , ஆரோக்கியம் மற்றும் மருத்துவ , லைம் நோய் ,

Via Illumina Accelerator, Flightpath Biosciences Launches Largest Clinical Biomarker Study in Lyme Disease

ENewsChannels NEWS: Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD). :: News from eNewsChannels ....

United States , Matt Tindall , Michael Bellas , Flightpath Biosciences , Illumina Accelerator , Persistent Lyme Disease , Flightpath Co Founder , Persistent Lyme , Mark De Souza , ஒன்றுபட்டது மாநிலங்களில் , மேட் டிண்டால் , மைக்கேல் பெல்லாஸ் , இல்லுமின முடுக்குப்பொறி , தொடர்ந்து லைம் நோய் , தொடர்ந்து லைம் , குறி டி ஸூஸ ,